MCID: BLD034
MIFTS: 56

Bile Duct Carcinoma malady

Categories: Rare diseases, Cancer diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Bile Duct Carcinoma

Aliases & Descriptions for Bile Duct Carcinoma:

Name: Bile Duct Carcinoma 12 14 69
Bile Duct Cancer 50 52 41
Bile Duct Neoplasms 42 69
Malignant Tumor of Extrahepatic Bile Duct 69
Carcinoma of Extrahepatic Bile Duct 69
Extrahepatic Bile Duct Cancer 50

Classifications:



External Ids:

Disease Ontology 12 DOID:4897
MeSH 42 D001650
NCIt 47 C27814
SNOMED-CT 64 70179006
UMLS 69 C0740277

Summaries for Bile Duct Carcinoma

MedlinePlus : 41 your liver makes a digestive juice called bile. your gallbladder stores it between meals. when you eat, your gallbladder pushes the bile into tubes called bile ducts. they carry the bile to your small intestine. the bile helps break down fat. it also helps the liver get rid of toxins and wastes. bile duct cancer is rare. it can happen in the parts of the bile ducts that are outside or inside the liver. cancer of the bile duct outside of the liver is much more common. risk factors include having inflammation of the bile duct, ulcerative colitis, and some liver diseases. symptoms can include jaundice itchy skin fever abdominal pain tests to diagnose bile duct cancer may include a physical exam, imaging tests of the liver and bile ducts, blood tests, and a biopsy. treatments include surgery, radiation therapy, and chemotherapy. nih: national cancer institute

MalaCards based summary : Bile Duct Carcinoma, also known as bile duct cancer, is related to giant cell tumor and adenosquamous bile duct carcinoma, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Bile Duct Carcinoma is MUC1 (Mucin 1, Cell Surface Associated), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Development ERBB-family signaling. The drugs Oxaliplatin and Etomidate have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and small intestine, and related phenotypes are cellular and digestive/alimentary

Disease Ontology : 12 A bile duct cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

Wikipedia : 71 Cholangiocarcinoma or bile duct cancer is a form of cancer that is composed of mutated epithelial cells... more...

Related Diseases for Bile Duct Carcinoma

Diseases related to Bile Duct Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 201)
id Related Disease Score Top Affiliating Genes
1 giant cell tumor 30.0 CDX2 KRT20 TP53
2 adenosquamous bile duct carcinoma 12.3
3 bile duct carcinoma in situ 12.1
4 common bile duct neoplasm 12.1
5 cholangiocarcinoma, susceptibility to 11.4
6 intrahepatic cholangiocarcinoma 11.3
7 biliary tract neoplasm 11.1
8 extrahepatic bile duct adenocarcinoma 11.0
9 bile duct adenocarcinoma 11.0
10 klatskin's tumor 11.0
11 distal biliary tract carcinoma 11.0
12 extrahepatic bile duct small cell adenocarcinoma 11.0
13 linitis plastica 10.4 CDH1 TP53
14 choroid epithelioid cell melanoma 10.3 CDX2 MUC2
15 gastrointestinal system cancer 10.3 CDH1 MUC1 MUC2
16 fibular collateral ligament bursitis 10.3 MUC1 MUC2 MUC4
17 embryonal testis carcinoma 10.3 CDH1 KRT20 MUC1
18 clitoris cancer 10.3 CDX2 KRT20 MUC1
19 acute eustachian salpingitis 10.3 CDH1 CDX2 MUC2
20 refractory plasma cell neoplasm 10.3 MUC1 MUC2 MUC4
21 estrogen-receptor positive breast cancer 10.3 CCND1 CDH1 TP53
22 cervix endometriosis 10.3 CDX2 KRT20 MUC2
23 brachydactyly, type b1 10.3 MUC1 MUC2 MUC4
24 spastic diplegia infantile type 10.3 CDX2 MUC1 MUC2
25 spastic ataxia 5 10.3 CDX2 KRT20 TP53
26 acquired hemangioma 10.3 CDX2 PTGS2 TP53
27 statin toxicity 10.3 CCND1 PTGS2 TP53
28 mesenchymoma 10.3 CDX2 KRT20 MUC1
29 childhood brain germinoma 10.3 MUC1 MYC TP53
30 fallopian tube leiomyosarcoma 10.3 CDH1 MUC1 MUC2 TP53
31 benign ependymoma 10.3 MUC1 MUC4 TP53
32 neuroendocrine tumor 10.3 CDX2 KRT20 PTGS2
33 maxillary sinus cholesteatoma 10.3 CCND1 CDH1 TP53
34 ovarian mucinous neoplasm 10.3 CDX2 PTGS2 TP53
35 small intestine carcinoid neuroendocrine tumor 10.3 KRT20 MUC1 MUC2 TP53
36 placental site trophoblastic tumor 10.3 KRT20 MUC1 MUC2 TP53
37 connective tissue benign neoplasm 10.3 CCND1 CDH1 TP53
38 sclerosing hemangioma 10.3 CDH1 CDX2 MUC1 MUC2
39 hepatitis 10.3
40 mitochondrial encephalomyopathy 10.3 KRT20 PTGS2 TP53
41 human granulocytic anaplasmosis 10.2 MUC1 MYC TP53
42 papillary transitional carcinoma 10.2 CCND1 CDH1 KRT20 TP53
43 paroxysmal nocturnal hemoglobinuria 10.2 CDH1 MUC1 MUC4 TP53
44 neurofibrosarcoma 10.2 CDX2 KRT20 MUC1 MUC2
45 pelvic inflammatory disease 10.2 CDX2 KRT20 MUC1 MUC2
46 extraocular retinoblastoma 10.2 CCND1 MYC TP53
47 breast signet ring cell adenocarcinoma 10.2 KRT7 MYC
48 neuroretinitis 10.2 CCND1 CDX2 KRT20 MUC2
49 pseudo-meigs syndrome 10.2 CDH1 FASLG MUC2
50 hyperornithinemia-hyperammonemia-homocitrullinemia syndrome 10.2 CDX2 PTGS2 TP53

Graphical network of the top 20 diseases related to Bile Duct Carcinoma:



Diseases related to Bile Duct Carcinoma

Symptoms & Phenotypes for Bile Duct Carcinoma

UMLS symptoms related to Bile Duct Carcinoma:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, gastrointestinal gas

MGI Mouse Phenotypes related to Bile Duct Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.11 CCND1 CDH1 CDX2 FASLG KRT19 KRT7
2 digestive/alimentary MP:0005381 9.97 CDH1 CDX2 FASLG KRT19 MUC2 MYC
3 homeostasis/metabolism MP:0005376 9.93 MYC PTGS2 TP53 ABCC2 ABCC3 CCND1
4 endocrine/exocrine gland MP:0005379 9.91 CCND1 CDH1 CDX2 FASLG KRT19 MUC2
5 integument MP:0010771 9.56 CCND1 CDH1 FASLG KRT19 MYC PTGS2
6 neoplasm MP:0002006 9.32 CCND1 CDH1 CDX2 FASLG KRT19 MGAT5

Drugs & Therapeutics for Bile Duct Carcinoma

Drugs for Bile Duct Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 260)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
2
Etomidate Approved Phase 4 33125-97-2 36339 667484
3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754 657311
4
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
5
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
6
Pancrelipase Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
7
Meperidine Approved Phase 4 57-42-1 4058
8
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
9
Coal tar Approved Phase 4 8007-45-2
10
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
11
Butyric Acid Experimental Phase 4 107-92-6 264
12 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1
13 Anesthetics Phase 4,Phase 3
14 Fibrin Tissue Adhesive Phase 4
15 Hemostatics Phase 4
16 Adjuvants, Anesthesia Phase 4,Phase 3
17 Anesthetics, General Phase 4,Phase 3
18 Anesthetics, Intravenous Phase 4,Phase 3
19 Anti-Anxiety Agents Phase 4,Phase 3
20 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1
21 Central Nervous System Depressants Phase 4,Phase 3
22 Cortisol succinate Phase 4
23 GABA Agents Phase 4
24 GABA Modulators Phase 4
25 Hydrocortisone 17-butyrate 21-propionate Phase 4
26 Hydrocortisone acetate Phase 4
27 Hydrocortisone-17-butyrate Phase 4
28 Hypnotics and Sedatives Phase 4
29 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
30 Psychotropic Drugs Phase 4,Phase 3
31 Tranquilizing Agents Phase 4,Phase 3
32 Anti-Bacterial Agents Phase 4,Phase 2,Phase 1
33 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 1
34 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 pancreatin Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Analgesics Phase 4,Phase 3
38 Analgesics, Opioid Phase 4,Phase 3
39 Narcotics Phase 4,Phase 3
40 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1
41 Antirheumatic Agents Phase 4,Phase 1
42 Analgesics, Non-Narcotic Phase 4
43 Anti-Inflammatory Agents, Non-Steroidal Phase 4
44 Cyclooxygenase 2 Inhibitors Phase 4
45 Cyclooxygenase Inhibitors Phase 4
46 arginine Nutraceutical Phase 4
47 Omega 3 Fatty Acid Nutraceutical Phase 4,Phase 1
48 Cola Nutraceutical Phase 4,Phase 3,Phase 1,Phase 2
49
Trioxsalen Approved Phase 2, Phase 3 3902-71-4 5585
50
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750

Interventional clinical trials:

(show top 50) (show all 350)
id Name Status NCT ID Phase
1 Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
2 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4
3 Winged Perimeter Versus Traditional Plastic Biliary Stent for Malignant Bile Duct Obstruction Unknown status NCT01514214 Phase 4
4 Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture Unknown status NCT01125865 Phase 4
5 Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm Unknown status NCT01351194 Phase 4
6 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
7 Randomised Trial Comparing Metal and Plastic Biliary Stents Stents for Palliating Malignant Jaundice Unknown status NCT00731419 Phase 4
8 Effects of Etomidate on Postoperative Circadian Rhythm Changes of Salivary Cortisol in Children Unknown status NCT02013986 Phase 4
9 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
10 Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Completed NCT01041612 Phase 4
11 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
12 RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction Completed NCT00980889 Phase 4
13 Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents Completed NCT01315522 Phase 4
14 Radiofrequency Ablation for Malignant Biliary Obstruction Completed NCT01758341 Phase 4
15 The Usefulness of Endoscopic Ultrasound-guided Biliary Drainage With a Newly Designed Hybrid Metallic Stent Completed NCT01862198 Phase 4
16 Spy II Clinical Registry Completed NCT00751998 Phase 4
17 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4
18 Extended Antibiotic Therapy in Postoperative of Laparoscopic Cholecystectomy in Acute Cholecystitis Recruiting NCT02057679 Phase 4
19 Laparoscopic Surgery Versus Radiofrequency Ablation for Recurrent HCC Active, not recruiting NCT02535117 Phase 4
20 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Enrolling by invitation NCT01111591 Phase 4
21 The Effect of Individualized Precision Therapy Programs in Patients With BTC Not yet recruiting NCT02943031 Phase 4
22 Laparoscopic Surgery VS RFA for Recurrent HCC Not yet recruiting NCT02785380 Phase 4
23 RFA RCT for Pancreatic or Bile Duct Cancer Unknown status NCT02166190 Phase 3
24 Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
25 Endoscopic Stenting Versus Surgical Bypass for Low Bile Duct Obstruction by Cancer of the Pancreatic Head Unknown status NCT00753441 Phase 2, Phase 3
26 Evaluation of A New Digestive Reconstruction Procedure Following Pancreatoduodenectomy Unknown status NCT01931449 Phase 3
27 Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma Unknown status NCT02108145 Phase 2, Phase 3
28 Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma Unknown status NCT01739465 Phase 2, Phase 3
29 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3
30 Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery Completed NCT00513539 Phase 3
31 Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors Completed NCT00262769 Phase 3
32 Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery Completed NCT00304135 Phase 2, Phase 3
33 Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer Completed NCT00363584 Phase 3
34 Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms Completed NCT01640522 Phase 3
35 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
36 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3
37 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
38 A Study of the WallFlex™ Biliary Fully-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction Completed NCT00433771 Phase 3
39 S-1 and Photodynamic Therapy in Cholangiocarcinoma Completed NCT00869635 Phase 3
40 Clinical Outcomes of EUS-guided Biliary Drainage Using Partially or Fully Covered Metallic Stents Completed NCT02114320 Phase 3
41 Comparison on the Efficacy of Endoscopic Snare Papillectomy With or Without Submucosal Injection Completed NCT02165852 Phase 3
42 Reduced Pancreatic Fistula Rate Following Pancreaticoduodenectomy: Trial on Pancreaticogastrostomy Versus Pancreaticojejunostomy Completed NCT00830778 Phase 3
43 Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas Completed NCT00844649 Phase 3
44 Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours Recruiting NCT02591030 Phase 2, Phase 3
45 Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures Recruiting NCT01721174 Phase 2, Phase 3
46 Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma Recruiting NCT01755013 Phase 2, Phase 3
47 Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy Recruiting NCT02853474 Phase 3
48 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Recruiting NCT02798510 Phase 3
49 Primary Needle Knife Fistulotomy Versus Conventional Cannulation Method Recruiting NCT02916199 Phase 3
50 Two Bilateral Metal Stenting in Hilar Malignancy Recruiting NCT01141088 Phase 3

Search NIH Clinical Center for Bile Duct Carcinoma

Cochrane evidence based reviews: bile duct neoplasms

Genetic Tests for Bile Duct Carcinoma

Anatomical Context for Bile Duct Carcinoma

MalaCards organs/tissues related to Bile Duct Carcinoma:

39
Liver, Testes, Small Intestine, Skin, Lymph Node, Pancreas, Colon

Publications for Bile Duct Carcinoma

Articles related to Bile Duct Carcinoma:

(show top 50) (show all 301)
id Title Authors Year
1
EGFR, COX2, p-AKT expression and PIK3CA mutation in distal extrahepatic bile duct carcinoma. ( 27020207 )
2016
2
Bile duct carcinoma recurrence in the papillary region in a long-term survivor of hilar cholangiocarcinoma: a case report. ( 27784337 )
2016
3
Intra-pancreatic Distal Bile Duct Carcinoma is Morphologically, Genetically, and Clinically Distinct from Pancreatic Ductal Adenocarcinoma. ( 26956004 )
2016
4
Intrapancreatic distal common bile duct carcinoma: Analysis, staging considerations, and comparison with pancreatic ductal and ampullary adenocarcinomas. ( 27469329 )
2016
5
Bile duct carcinoma associated with congenital biliary dilatation in a 16-year-old female: a case report and literature review. ( 26943681 )
2016
6
Polypoid extrahepatic bile duct carcinoma morphologically indistinguishable from benign giant cell tumor. ( 26256450 )
2015
7
Expression and Significance of COX-2 and Ki-67 in Hepatolithiasis with Bile Duct Carcinoma. ( 26423666 )
2015
8
A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine. ( 26001650 )
2015
9
Bilateral ovarian metastasis from distal common bile duct carcinoma developing after choledochal cyst excision. ( 26155281 )
2015
10
Abnormal increased re-released Hb from RBCs of an intrahepatic bile duct carcinoma patient was detected by electrophoresis release test. ( 26405982 )
2015
11
A novel technique for endoscopic transpapillary "mapping biopsy specimens" of superficial intraductal spread of bile duct carcinoma (with videos). ( 24674353 )
2014
12
How to access photodynamic therapy for bile duct carcinoma. ( 25332999 )
2014
13
A case of occupational bile duct carcinoma following exposure to a chlorinated organic solvent in the printing industry that was recognized as a work-related accident. ( 25482911 )
2014
14
When hepatic-side ductal margin is positive in N+ cases, additional resection of the bile duct is not necessary to render the negative hepatic-side ductal margin during surgery for extrahepatic distal bile duct carcinoma. ( 24657986 )
2014
15
Characterization of two novel cell lines with distinct heterogeneity derived from a single human bile duct carcinoma. ( 23382894 )
2013
16
Pancreaticobiliary maljunction is associated with common bile duct carcinoma: a meta-analysis. ( 24489507 )
2013
17
Synergic effect of photodynamic therapy using talaporfin sodium with conventional anticancer chemotherapy for the treatment of bile duct carcinoma. ( 22835954 )
2013
18
Differential expression of basement membrane type IV collagen I+2 and I+6 chains as a prognostic factor in patients with extrahepatic bile duct carcinoma. ( 22927259 )
2013
19
Diagnostic and prognostic value of immunohistochemical expression of S100P and IMP3 in transpapillary biliary forceps biopsy samples of extrahepatic bile duct carcinoma. ( 23269460 )
2013
20
Bile duct carcinoma involving the common channel associated with pancreaticobiliary maljunction shows an extension pattern similar to ductal carcinoma of the pancreas. ( 23957917 )
2013
21
Descriptive epidemiology of bile duct carcinoma in Osaka. ( 24014885 )
2013
22
Chemoradiation and brachytherapy in extrahepatic bile duct carcinoma. ( 24289902 )
2013
23
Bile aspiration cytology in diagnosis of bile duct carcinoma: factors associated with positive yields. ( 21785970 )
2012
24
Adenocarcinoma with pyloric gland phenotype of the extrahepatic bile ducts: a previously unrecognized and distinctive morphologic variant of extrahepatic bile duct carcinoma. ( 22795356 )
2012
25
Photodynamic therapy using talaporfin sodium (LaserphyrinAr) for bile duct carcinoma: a preliminary clinical trial. ( 23155262 )
2012
26
Duct of Luschka diagnosed by sonography in a patient with bile duct carcinoma and intrahepatic bile duct dilatation. ( 23055263 )
2012
27
Extended right hepatectomy for hilar bile duct carcinoma using the modified liver hanging maneuver. ( 22683977 )
2012
28
Post-cholecystectomy amputation neuroma mimicking common bile duct carcinoma. ( 21861328 )
2011
29
Down-regulation of c-Myc expression inhibits the invasion of bile duct carcinoma cells. ( 21557726 )
2011
30
Aggressive hilar inflammatory myofibroblastic tumor with hilar bile duct carcinoma in situ. ( 22319741 )
2011
31
Advantages of laserphyrin compared with photofrin in photodynamic therapy for bile duct carcinoma. ( 21360081 )
2011
32
Endoscopic diagnosis of extrahepatic bile duct carcinoma: Advances and current limitations. ( 21611097 )
2011
33
Extensively spreading intraepithelial bile duct carcinoma causing multiple bile duct strictures: report of three cases. ( 21969205 )
2011
34
Impact of residual in situ carcinoma on postoperative survival in 125 patients with extrahepatic bile duct carcinoma. ( 19521656 )
2010
35
The ratio between metastatic and examined lymph nodes is an independent prognostic factor for patients with resectable middle and distal bile duct carcinoma. ( 19596119 )
2010
36
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. ( 20224968 )
2010
37
Pancreatoduodenectomy for local intrapancreatic recurrence after bile duct resection of mid bile duct carcinoma. ( 21410028 )
2010
38
Expression of the extracellular matrix protein periostin in liver tumours and bile duct carcinomas. ( 20459570 )
2010
39
Decreased expression of focal adhesion kinase is associated with a poor prognosis in extrahepatic bile duct carcinoma. ( 20185162 )
2010
40
Prognostic significance of fascin expression in extrahepatic bile duct carcinomas. ( 19556073 )
2009
41
Pyogenic liver abscess complicating early bile duct carcinoma in the middle bile duct: a rare presentation. ( 19252355 )
2009
42
67-kDa laminin receptor in human bile duct carcinoma. ( 19182490 )
2009
43
Choleretic effect of inchinkoto, a herbal medicine, on livers of patients with biliary obstruction due to bile duct carcinoma. ( 19054142 )
2009
44
Main bile duct carcinoma management. Our experience on 38 cases. ( 19681291 )
2009
45
Antiproliferation and apoptosis induced by tamoxifen in human bile duct carcinoma QBC939 cells via upregulated p53 expression. ( 19460356 )
2009
46
Depth of tumor invasion better predicts prognosis than the current American Joint Committee on Cancer T classification for distal bile duct carcinoma. ( 19628081 )
2009
47
Three-dimensional cholangiography applying C-arm computed tomography in bile duct carcinoma: a new radiological technique. ( 19621666 )
2009
48
Eosinophilic cholangitis with obstructive jaundice mimicking bile duct carcinoma. ( 19194647 )
2009
49
Usefulness of measuring hepatic functional volume using Technetium-99m galactosyl serum albumin scintigraphy in bile duct carcinoma: report of two cases. ( 19183831 )
2009
50
IMP3 expression in lesions of the biliary tract: a marker for high-grade dysplasia and an independent prognostic factor in bile duct carcinomas. ( 19467694 )
2009

Variations for Bile Duct Carcinoma

Cosmic variations for Bile Duct Carcinoma:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM521 KRAS biliary tract,gallbladder,other,inflammation c.35G>A p.G12D 4

Expression for Bile Duct Carcinoma

Search GEO for disease gene expression data for Bile Duct Carcinoma.

Pathways for Bile Duct Carcinoma

Pathways related to Bile Duct Carcinoma according to GeneCards Suite gene sharing:

(show all 28)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.29 CCND1 FASLG MUC1 MYC NCAM1 PTGS2
2
Show member pathways
12.44 CCND1 CDH1 MUC1 MYC TP53
3 12.44 CCND1 CDH1 FASLG MYC PTGS2 TP53
4 12.4 CDH1 KRT19 KRT20 KRT7 MUC1
5
Show member pathways
12.31 CCND1 FASLG MYC TP53
6 12.27 CCND1 CDH1 MYC TP53
7 12.27 CCND1 CDH1 MYC PTGS2 TP53
8
Show member pathways
12.26 CCND1 CDH1 MYC TP53
9 12.19 CCND1 FASLG MYC TP53
10 12.05 CCND1 CDH1 MYC TP53
11 11.94 CDX2 KRT19 MYC NCAM1
12 11.87 CCND1 CDH1 MYC PTGS2 TP53
13 11.84 CCND1 MYC PTGS2 TP53
14 11.79 CCND1 FASLG MYC TP53
15 11.75 CCND1 MYC TP53
16 11.7 CCND1 CDH1 MYC
17 11.69 CCND1 MYC PTGS2
18 11.63 ABCC2 FASLG TP53
19 11.63 CCND1 MYC PTGS2 TP53
20 11.49 CCND1 CDH1 MYC TP53
21 11.46 CCND1 FASLG TP53
22 11.44 CCND1 MYC TP53
23 11.36 CCND1 MYC TP53
24 11.21 KRT19 PTGS2 TP53
25 11.16 CCND1 FASLG MUC1 MYC PTGS2 TP53
26 11.06 CCND1 FASLG MYC PTGS2 TP53
27 10.92 CCND1 CDH1 MYC TP53
28 10.6 ABCC2 ABCC3

GO Terms for Bile Duct Carcinoma

Cellular components related to Bile Duct Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.65 CDH1 FASLG KRT19 KRT7 KRT9 MGAT5
2 intermediate filament GO:0005882 8.92 KRT19 KRT20 KRT7 KRT9

Biological processes related to Bile Duct Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.91 CCND1 CDX2 FASLG MYC PTGS2
2 keratinization GO:0031424 9.73 KRT19 KRT20 KRT7 KRT9
3 response to drug GO:0042493 9.65 ABCC2 CCND1 CDH1 MYC PTGS2
4 response to estrogen GO:0043627 9.63 ABCC2 CCND1 KRT19
5 O-glycan processing GO:0016266 9.58 MUC1 MUC2 MUC4
6 ATP hydrolysis coupled anion transmembrane transport GO:0099133 9.54 ABCC2 ABCC3
7 ovulation GO:0030728 9.52 MYC PTGS2
8 cellular response to UV GO:0034644 9.5 MYC PTGS2 TP53
9 maintenance of gastrointestinal epithelium GO:0030277 9.49 MUC2 MUC4
10 mitotic G1 DNA damage checkpoint GO:0031571 9.48 CCND1 TP53
11 cellular chloride ion homeostasis GO:0030644 9.37 ABCC2 FASLG
12 cornification GO:0070268 9.26 KRT19 KRT20 KRT7 KRT9
13 re-entry into mitotic cell cycle GO:0000320 9.16 CCND1 MYC
14 response to organic substance GO:0010033 8.92 CCND1 CDH1 PTGS2 S100P

Molecular functions related to Bile Duct Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 ATPase-coupled anion transmembrane transporter activity GO:0043225 8.62 ABCC2 ABCC3

Sources for Bile Duct Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....